Medications for Amyloidosis

3 results
Alnylam Pharmaceuticals, Inc.
Usage: AMVUTTRA is indicated for treating the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) and the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults, focusing on reducing cardiovascular mortality, hospitalizations, and urgent heart failure visits.
Alnylam Pharmaceuticals, Inc.
Usage: ONPATTRO is indicated for treating polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adults.
Acer Therapeutics Inc.
Usage: TEGSEDI is indicated for treating polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adults.